Allos Therapeutics Inc - Current report filing (8-K)
21 Juillet 2008 - 2:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 21, 2008
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Events.
On July 21, 2008,
Allos Therapeutics, Inc., a Delaware
corporation (the Company), issued a
press release announcing the initiation of a Phase 2, open-label,
single-arm, multi-center study of PDX (pralatrexate) in patients with advanced
or metastatic relapsed transitional cell carcinoma of the urinary bladder. The
press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
99.1
|
|
Press
Release, dated July 21, 2008, entitled Allos Therapeutics Initiates Phase 2 Study of PDX in Patients with
Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary
Bladder.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 21,
2008
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President and General Counsel
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated July 21, 2008, entitled Allos Therapeutics Initiates Phase 2 Study of PDX in Patients with
Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary
Bladder.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024